The Manufacturers Life Insurance Company Acquires 161,845 Shares of Erasca, Inc. $ERAS

The Manufacturers Life Insurance Company raised its holdings in shares of Erasca, Inc. (NASDAQ:ERAS) by 295.5% during the first quarter, according to its most recent filing with the SEC. The firm owned 216,614 shares of the company’s stock after purchasing an additional 161,845 shares during the period. The Manufacturers Life Insurance Company owned 0.07% of Erasca worth $3,505,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of ERAS. BNP Paribas Financial Markets increased its holdings in Erasca by 58.0% during the second quarter. BNP Paribas Financial Markets now owns 21,579 shares of the company’s stock valued at $27,000 after buying an additional 7,923 shares during the period. EP Wealth Advisors LLC purchased a new stake in Erasca during the second quarter worth $29,000. Russell Investments Group Ltd. bought a new stake in Erasca during the 3rd quarter valued at $31,000. EntryPoint Capital LLC bought a new stake in Erasca during the 4th quarter valued at $38,000. Finally, Stifel Financial Corp purchased a new position in shares of Erasca in the 4th quarter valued at $38,000. Institutional investors own 67.78% of the company’s stock.

Erasca News Roundup

Here are the key news stories impacting Erasca this week:

• Negative Sentiment: Several firms, including Hagens Berman, allege that Erasca and certain executives misled investors about the competitive advantages, safety profile and intellectual-property protection of ERAS-0015, the company’s lead oncology candidate. These are allegations, not proven findings. Hagens Berman Erasca class action alert
• Negative Sentiment: The lawsuit covers investors who purchased Erasca securities from January 14, 2025, through April 26, 2026. Continued legal notices could increase reputational, financial and disclosure risks for the biotechnology company and contribute to volatility. Bronstein Gewirtz Grossman Erasca lawsuit announcement
• Neutral Sentiment: Investors have until August 10, 2026, to apply to become lead plaintiff. The many releases issued by investor-rights firms primarily seek clients and repeat the same deadline; they do not represent new clinical, regulatory or financial information from Erasca. Kahn Swick and Foti Erasca deadline notice

Erasca Price Performance

Shares of ERAS opened at $18.41 on Friday. The company’s fifty day moving average price is $16.80 and its 200-day moving average price is $14.73. Erasca, Inc. has a 1-year low of $1.33 and a 1-year high of $24.28. The firm has a market capitalization of $5.73 billion, a PE ratio of -19.80 and a beta of 0.66.

Erasca (NASDAQ:ERAS) last issued its earnings results on Monday, May 11th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.48). As a group, research analysts anticipate that Erasca, Inc. will post -0.54 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently commented on ERAS shares. Wall Street Zen lowered Erasca from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Mizuho cut their target price on Erasca from $28.00 to $26.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 12th. Stifel Nicolaus boosted their target price on shares of Erasca from $20.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, April 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Erasca in a research report on Thursday, June 11th. Finally, HC Wainwright reissued a “buy” rating on shares of Erasca in a research report on Tuesday, July 14th. Eight research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $21.64.

Erasca Profile

Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.